In 2003, Flagship Ventures co-led with Polaris Ventures a seed financing of Pervasis Therapeutics, a developer of novel, cell-based medical devices intended to combine the therapeutic efficacy of drugs with the dynamic and multi-factorial responsiveness of human cells. Pervasis offers a broad therapeutic vision complemented by a near-term product development opportunity addressing significant unmet clinical needs in vascular medicine. World-class co-founders, Bob Langer and Elazer Edelman of MIT, are experts in polymer science and cardiovascular medicine. Flagship Managing Partner Ed Kania is a Director.

www.pervasistx.com